more people suffer from musculoskeletal diseases than of the circulatory or respiratory system. Despite the hundreds of millions of patients, common diagnosis methods seem to be stuck in the 20th century. Manual interpretation of X-rays or MRI-images by trained experts is still the norm. Subjective and time consuming, these methods are not standardised and accuracies depend on individual competences.
With this collaboration,
the companies aim to target the DACH region and offer a single, comprehensive solution for MSK imaging, encompassing measurement, scoring, and fracture detection workflows, thereby providing the most comprehensive software package available. Their innovative, MDR and FDA-cleared analysis tools are already in clinical use at over 200 medical and academic institutions throughout the EU and US. To date, both companies were offering their AI based platforms as individual solutions for a standardised, effective and precise diagnosis of chronic and traumatic MSK conditions, offering a range of modules that are optimised for specific bone systems of the body such as knee, hip, hand, spine and others.
Despite a growing number of MSK-specific solutions, end-users lack a complete, one-stop-shop solution for addressing the multitude of diagnostic use cases. Often, existing solutions do not adequately address the specific needs of radiologists, orthopaedic-and trauma surgeons. To close this diagnostic gap, the two leading AI companies in that space have agreed to combine their expertise and market knowledge in order to offer a complete and comprehensive solution.
Dr. Richard Ljuhar, CEO and Co-Founder of ImageBiopsy Lab:
"Understanding the diagnostic workflow and needs of physicians are the key elements before even starting to think of the use of AI. For years now, we have been working closely with leading MSK radiologists, orthopaedics and traumatologists to not just understand how AI can play a role in MSK diagnostics, but also to discover how solutions can be seamlessly integrated into existing workflows. We have made it our vision to transform the entire diagnostic MSK value chain for the benefit of practitioners, patients and the overall healthcare system. We see Radiobotics as the logical partner to offer best in class solutions for MSK conditions diagnostics, from measurements and scoring to fracture detection. Such collaborations are the next step in the evolution of AI-powered workflow integrations and we are excited to partner with Radiobotics on this journey.”
Mads Jarner, CEO and Co-Founder of Radiobotics:
“As we acknowledge growing field and interest in adopting MSK AI-solutions into the clinical workflow, we see a clear advantage for clinics to get access to combined and more comprehensive solutions, why we are really happy to be able to work with ImageBiopsy Lab, ensuring that customers can leverage getting easier access to the market leading solutions that we’ve both built. With ImageBiopsy Labs’ expertise and deep network in the German speaking regions, we are excited to be able to offer our fracture detection solution RBfracture™ in this region initially, and hope to be able to expand into other areas.”
The AI-based MSK-focused platforms developed by ImageBiopsy Lab and Radiobotics offer a novel way to translate imaging data efficiently into objective, structured health information. With this collaboration, both companies aim to jointly focus on selected key regions to become the leading software provider in the MSK field.